The efficiency of gonadotropin- releasing hormone (GnRH) agonist pretreatment in frozen- thawed embryo transfer cycles

The efficiency of gonadotropin- releasing hormone (GnRH) agonist for pituitary suppression in frozen-thawed embryo transfer cycles to establish higher pregnancy rate remained debatable. The aim of present study was to compare pregnancy outcome between patients with and without GnRH agonist pretreatment in frozen- thawed embryo transfer (FET) cycles.Two hundred seventy four patients, who had undergone FET cycles, were retrospectively analyzed. Patients were divided into 2 groups: with GnRH agonist pretreatment (group A, n=137) and without GnRH agonist pretreatment (group B, n=137). In both groups endometrial preparation was started from cycle day two. In group A, daily buserelin acetate at decreasing dosage from 30 mcg to 20 mcg was administrated in mid luteal phase of preceding cycle and given for 14 days. In both groups, patients received oral estradiol valerate at an increasing dosage from 4 mg to 8mg. The number of total thawed embryos replaced is different between groups.There were not any significant differences in mean age (32.0±5.3 vs 31.9±5.4, P= 0.8), basal FSH (4.6± 2.6 vs 4.7± 1.7, P=0.9), number of previous FET cycles (1.6±1.4 vs 1.8±1.8, P=0.5), total collected (13.8±8.0 vs 13.2±6.8, P=0.5) and metaphase II (11.0±6.5 vs 10.0±6.0, P=0.2) oocytes and embryos (8.6±5.3 vs 7.6±4.9, P=0.1). Group A and B didn’t differ in rate of chemical pregnancy (41% vs 37.6%, P=0.5).It seems that there is no difference in pregnancy rate following FET between patients undergoing pituitary suppression and who didn’t receive GnRH agonist pretreatment.

کلیدواژه ها:

Buserelin ، Cryopreservation ، Pregnancy